Eating

Zepbound vs Wegovy: Head-to-Head Trial, Doses, Cost and How They Differ (2026)

Jeff Zorn · · 15 min read

Share

By Jeff Zorn, founder of Zornava. Former college basketball player, degree in exercise science and nutrition, two years on GLP-1 medications. My experience, not medical advice. Talk to your prescriber or a registered dietitian about your own situation.

Published · Last reviewed

Short answer: Zepbound (tirzepatide, Eli Lilly) acts on two hormone receptors, GIP and GLP-1; Wegovy (semaglutide, Novo Nordisk) acts on GLP-1 alone.[1][2] In SURMOUNT-5, the one head-to-head trial, body weight fell by an average of 20.2% over 72 weeks on tirzepatide and 13.7% on semaglutide, each at the highest dose people tolerated.[3] Wegovy has approvals Zepbound does not, for heart risk and a fatty liver disease, plus a daily pill; Zepbound is approved for obstructive sleep apnea.[2][1]

Which one suits a person is a decision for that person and their prescriber, and both work best alongside eating well on a smaller appetite, the subject of our guide to what to eat when you're eating less. General information, not medical advice. Everything below is from the FDA labels, the published trials and the makers' own price pages, as of November 13, 2026.

Zepbound vs Wegovy at a glance

Zepbound Wegovy
Maker and molecule Eli Lilly; tirzepatide (also sold as Mounjaro for type 2 diabetes)[1] Novo Nordisk; semaglutide (also sold as Ozempic and Rybelsus for type 2 diabetes)[2]
Receptors GIP and GLP-1[1] GLP-1[2]
FDA-approved uses (date) Chronic weight management in adults (November 8, 2023); moderate to severe obstructive sleep apnea in adults with obesity (December 20, 2024)[4] Chronic weight management in adults (June 4, 2021) and ages 12 and up (December 23, 2022); lowering heart attack, stroke and cardiovascular death risk in adults with heart disease (March 8, 2024); MASH with moderate to advanced liver fibrosis, accelerated approval (August 15, 2025)[5]
Forms Weekly injection: single-dose pen, single-dose vials, or a 4-dose KwikPen. No pill.[1] Weekly injection (pen), and since December 22, 2025 a daily tablet, the "Wegovy pill"[2][5]
Label dose range Starts at 2.5 mg; maintenance 5, 10 or 15 mg; maximum 15 mg[1] Injection starts at 0.25 mg; maintenance 1.7 or 2.4 mg, up to 7.2 mg for adults. Tablet starts at 1.5 mg; maintenance 25 mg[2]
Headline placebo trial SURMOUNT-1, 72 weeks: body weight −15.0%, −19.5% and −20.9% on 5, 10 and 15 mg vs −3.1% on placebo[6] STEP 1, 68 weeks: −14.9% on 2.4 mg vs −2.4% on placebo.[7] STEP UP, 72 weeks: −18.8% on 7.2 mg[2]
Head to head (SURMOUNT-5, 72 weeks) Body weight −20.2%; waist −18.4 cm[3] Body weight −13.7%; waist −13.0 cm[3]
Most common digestive adverse reactions (label, drug vs placebo) 5 / 10 / 15 mg: nausea 25% / 29% / 28% vs 8%; diarrhea 19% / 21% / 23% vs 8%; constipation 17% / 14% / 11% vs 5%; vomiting 8% / 11% / 13% vs 2%[1] 2.4 mg injection: nausea 44% vs 16%; diarrhea 30% vs 16%; constipation 24% vs 11%; vomiting 24% vs 6%[2]
Boxed warning The same on both: risk of thyroid C-cell tumors, seen in rodents, human relevance unknown. Not for anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2.[1][2]
Maker's self-pay price (November 2026) Vials or KwikPen through LillyDirect: $299 a month for 2.5 mg, $399 for 5 mg, $449 for 7.5 to 15 mg with on-time refills[8] Injection $349 a month (0.25 to 2.4 mg), $399 for 7.2 mg; pill $149 to $299 by strength[9]

The adverse reaction rows come from each drug's own placebo trials, in different people, so they are not a ranking. The labels say rates from one drug's trials cannot be compared directly with another's.[1] The head-to-head row is the only like-for-like comparison. Each medicine has its own reference page: tirzepatide (Zepbound, Mounjaro) and semaglutide (Wegovy, Ozempic).

What did the head-to-head trial, SURMOUNT-5, find?

SURMOUNT-5 is the only trial so far to put Zepbound's and Wegovy's active ingredients side by side for weight management. It was published in the New England Journal of Medicine in 2025 and funded by Eli Lilly, the maker of tirzepatide.[3]

  • Who took part: 751 adults with obesity and without type 2 diabetes, randomized one to one.[3]
  • Design: phase 3b and open-label, so participants and investigators knew who was on which drug. There was no placebo group.[3]
  • Doses: each person took the maximum dose they tolerated, once a week for 72 weeks: tirzepatide 10 or 15 mg, or semaglutide 1.7 or 2.4 mg.[3]
SURMOUNT-5 result at 72 weeks Tirzepatide Semaglutide
Average change in body weight −20.2% −13.7%
Average change in waist circumference −18.4 cm −13.0 cm
Reached a 10% reduction or more 87.7% 66.7%
Reached a 20% reduction or more 55.0% 31.1%
Reached a 25% reduction or more 36.5% 18.6%
Stopped treatment because of an adverse event 6.1% 8.0%
Completed the study 319 of 375 319 of 376

Sources: the paper for weight and waist,[3] the posted results on ClinicalTrials.gov for the responder shares and completion,[10] and trade-press reporting of the paper for discontinuations.[11] Both differences in weight and waist were statistically significant.[3] Comparing only the top doses, 15 mg against 2.4 mg, the averages were −21.8% and −15.4%.[10]

How to read it. The result is solid on its main question, but three limits matter. The trial was open-label, which can affect how people report symptoms and whether they stay on treatment. It was sponsored by Lilly. And it compared the 2.4 mg Wegovy dose, not the 7.2 mg dose approved in March 2026, which reached −18.8% in its own placebo trial.[2][5] No trial has compared Zepbound 15 mg with Wegovy 7.2 mg. The adverse events are in the side effects section below.

Is Zepbound better than Wegovy?

On average change in body weight at 72 weeks, yes: tirzepatide came out ahead in SURMOUNT-5.[3] "Better" for one person depends on more than that average, and these are the points a prescriber weighs:

  • Other conditions. Wegovy is the one approved to lower heart attack and stroke risk in people with heart disease, and for MASH; Zepbound is the one approved for obstructive sleep apnea.[2][1]
  • Form. Some people prefer a daily tablet to a weekly shot; only Wegovy has one.[2]
  • Tolerability. Individual responses vary, and a dose that is not tolerated does not help.
  • Cost and coverage, which differ by plan and are set out below.

Averages also hide a wide spread: in SURMOUNT-5, about one in eight people on tirzepatide and one in three on semaglutide did not reach a 10% reduction.[10]

Why do they work differently?

Semaglutide is a long-acting copy of GLP-1 (glucagon-like peptide-1), a gut hormone released after eating. It acts on appetite centers in the brain, raises insulin release when blood sugar is high, lowers glucagon and slows stomach emptying.[2]

Tirzepatide is a single molecule that activates the GLP-1 receptor and the receptor for a second gut hormone, GIP (glucose-dependent insulinotropic polypeptide). The Zepbound label says nonclinical studies suggest GIP may add to the regulation of food intake; both receptors sit in brain areas involved in appetite.[1] Tirzepatide is therefore called a dual agonist.

Both labels say the drugs lower body weight with more fat mass lost than lean mass,[1][2] but lean mass still falls, which is why protein matters on either. They also clear the body at different speeds: the half-life is about 5 days for tirzepatide and about 1 week for semaglutide, which stays in the circulation for 5 to 7 weeks after the last dose.[1][2]

What are they approved for beyond body weight?

Approved use Medicine Trial behind it
Lowering the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight Wegovy injection (March 8, 2024) and tablets[5] SELECT: 17,604 adults without diabetes; events in 6.5% vs 8.0% on placebo, a 20% lower risk[12]
MASH, a fatty liver disease, with moderate to advanced fibrosis (accelerated approval) Wegovy injection (August 15, 2025)[5] ESSENCE: steatohepatitis resolved without worsening fibrosis in 63% vs 34%[13]
Moderate to severe obstructive sleep apnea in adults with obesity Zepbound (December 20, 2024)[4] SURMOUNT-OSA: breathing interruptions fell by 25.3 and 29.3 an hour vs 5.3 and 5.5 on placebo[14]
Weight management in adolescents 12 and up Wegovy injection (December 23, 2022)[5] Zepbound is approved for adults only[1]

For type 2 diabetes, the same molecules are sold under other names, Mounjaro and Ozempic, and in that population tirzepatide was compared with semaglutide 1 mg in SURPASS-2, where it lowered HbA1c and body weight more.[15]

Zepbound and Wegovy dosing: what the labels say

Both start low and step up, to reduce digestive reactions. The schedules below are reproduced so you can see what each label says, not so you can follow them yourself.

What the FDA labels say — not dosing advice; your prescriber sets your dose.[1][2]
Zepbound (weekly injection) Wegovy (weekly injection) Wegovy pill (daily)
Starting dose 2.5 mg for 4 weeks 0.25 mg for 4 weeks 1.5 mg for 30 days
Steps Up by 2.5 mg after at least 4 weeks on each dose 0.5, 1 and 1.7 mg, 4 weeks each 4 mg, then 9 mg, 30 days each
Maintenance 5, 10 or 15 mg (10 or 15 mg for sleep apnea) 2.4 mg (or 1.7 mg); up to 7.2 mg for adults after at least 4 weeks on 2.4 mg 25 mg
Missed dose Take within 4 days; after that, skip it Take if the next dose is more than 2 days away; if 2 or more doses in a row are missed, restart the steps at a lower dose Skip it and take the next day's dose
Food rule Any time of day, with or without meals Any time of day, with or without meals Empty stomach, up to 4 oz of plain water, then wait 30 minutes

Zepbound vs Wegovy side effects, side by side

Digestive reactions are the most common on both, mostly while the dose is being raised.[1][2] The label figures come from separate trials. SURMOUNT-5 is the one place they were counted in the same trial, under the same conditions:

Adverse event, SURMOUNT-5 (72 weeks) Tirzepatide (374 people) Semaglutide (376 people)
Nausea 43.6% 44.4%
Constipation 27.0% 28.5%
Diarrhea 23.5% 23.4%
Vomiting 15.0% 21.3%
Acid reflux (GERD) 6.1% 10.6%
Injection site reaction 8.6% 0.3%
Hair loss 8.3% 6.1%

Source: the posted results on ClinicalTrials.gov.[10] The paper reports that most digestive events were mild to moderate and came mainly during dose escalation.[3] With no placebo group, the table cannot say how much of each figure is the drug.

From the labels, against placebo:

  • Stopping for an adverse reaction: 4.8% to 6.7% on Zepbound by dose vs 3.4% on placebo in SURMOUNT-1;[1] 6.8% on Wegovy 2.4 mg vs 3.2%, mostly for nausea, vomiting or diarrhea.[2]
  • Severe digestive reactions: 1.7% to 3.1% on Zepbound vs 1%;[1] 4.1% on Wegovy vs 0.9%. Neither is recommended with severe gastroparesis.[2]
  • Dysesthesia (unusual skin sensations): 2% on Wegovy 2.4 mg vs 1%, and 22% on 7.2 mg.[2]
  • Shared warnings: pancreatitis, gallbladder disease, kidney injury from dehydration, serious allergic reactions, low blood sugar with insulin or a sulfonylurea, worsening diabetic eye disease and breathing in stomach contents under anesthesia.[1][2]
  • Birth control pills: only the Zepbound label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and after each dose increase.[1]
  • Pregnancy: the Wegovy label says to stop at least 2 months before a planned pregnancy, because of semaglutide's long half-life; the Zepbound label says to stop when pregnancy is recognized.[2][1]

How much do Zepbound and Wegovy cost?

Prices change often. These are the makers' own figures as of November 13, 2026.

  • Zepbound, self-pay: vials and multi-dose KwikPens are sold only through LillyDirect, with a prescription.[16] The price is $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 to 15 mg under an offer that requires refilling on time; otherwise $499 for 7.5 mg and $699 for 10 to 15 mg.[8]
  • Zepbound, with insurance: the single-dose pen can be as little as $25 with commercial coverage, or as low as $499 a month with commercial insurance that does not cover it, under a savings card that ends December 31, 2026.[8]
  • Wegovy, self-pay: $349 a month for the injection at any dose from 0.25 to 2.4 mg; new patients pay $199 for their first two fills of 0.25 or 0.5 mg through December 31, 2026. The 7.2 mg dose is $399. The pill is $149 for 1.5 mg, $199 for 4 mg and $299 for 9 or 25 mg.[9]
  • Wegovy list price: Novo Nordisk will cut the list price of Wegovy and Ozempic to $675 a month from January 1, 2027, about 50% off Wegovy. It said the change does not affect self-pay prices.[17] The list price matters mostly to people whose insurance charges coinsurance or a deductible.

Medicare. Part D is barred by law from covering drugs used for obesity alone.[18] The Medicare GLP-1 Bridge, a CMS demonstration from July 1, 2026 to December 31, 2027, gives eligible Part D beneficiaries certain GLP-1 drugs for a $50 copay, with prior authorization.[19] Lilly lists Zepbound under the Bridge,[8] and CMS's related BALANCE model names Wegovy and the Zepbound KwikPen among its drugs.[20]

Employer plans. In KFF's 2026 survey, 18% of firms with 200 or more workers covered GLP-1 medications used mainly for obesity.[21] Coverage, prior authorization and which brand is preferred vary by plan, so the plan's formulary often settles the choice. Compounded copies of either are not FDA-approved products; see compounded GLP-1s explained.

Switching from Wegovy to Zepbound, or back

Neither label has instructions for switching from the other, and neither gives a dose conversion. What the labels do say:

  • Not together. The Zepbound label says not to combine it with any GLP-1 receptor agonist, and the Wegovy label says the same of any other GLP-1 receptor agonist.[1][2] So a switch means stopping one before starting the other.
  • Starting doses. Each label's schedule begins at its starting dose, 2.5 mg for Zepbound and 0.25 mg for the Wegovy injection, and makes no exception for people coming from another GLP-1 medication.[1][2]
  • Overlap in the body. Semaglutide stays in the circulation for 5 to 7 weeks after the last dose;[2] tirzepatide's half-life is about 5 days.[1]
  • The only switch the Wegovy label does describe is between its own forms: from the 2.4 mg injection to the 25 mg tablet one week after the last injection, and from the tablet to the 2.4 mg injection the day after the last tablet.[2]

The timing and the starting dose of a switch are your prescriber's decision. Lists of "conversion charts" online come from clinics and sellers, not from the labels, and we do not reproduce them.

What to eat on either one

Neither label names a diet: both pair the drug with a reduced-calorie diet and more activity.[1][2] The 2025 joint advisory from four US medical and nutrition societies sets the same priorities for every GLP-1 medication: protein first, small nutrient-dense meals, fiber from food, deliberate fluids and strength training to protect lean mass.[22] Our pages go one question at a time:

For transparency about why this page exists on our site: we make one product, Zornava Replenish, a lemon-lime daily hydration and nutrient powder for lighter appetite days, including for people on GLP-1 medications. It is a dietary supplement, not a medication, and it does not replace or imitate any medicine on this page. It is not on sale yet; early access opens February 9, 2027, and the early-access list is open now.

Frequently asked questions

What is the difference between Zepbound and Wegovy?

Zepbound is tirzepatide from Eli Lilly, which activates two hormone receptors, GIP and GLP-1. Wegovy is semaglutide from Novo Nordisk, which activates GLP-1 only. Both are weekly injections for chronic weight management; Wegovy also comes as a daily pill and is approved for heart risk and MASH, while Zepbound is approved for obstructive sleep apnea.

Is Zepbound better than Wegovy?

In SURMOUNT-5, the only head-to-head trial, body weight fell by an average of 20.2% on tirzepatide and 13.7% on semaglutide over 72 weeks. That trial was open-label, funded by Lilly and used Wegovy 2.4 mg, not the newer 7.2 mg dose. Which is better for a given person also depends on other conditions, form, tolerability and cost.

Which has fewer side effects, Zepbound or Wegovy?

Neither clearly. In SURMOUNT-5, nausea was about equal (43.6% vs 44.4%), vomiting was lower on tirzepatide (15.0% vs 21.3%), injection site reactions were higher (8.6% vs 0.3%), and 6.1% vs 8.0% stopped treatment because of an adverse event. The trial had no placebo group and was open-label.

Can you switch from Wegovy to Zepbound?

That is a decision for your prescriber, and neither FDA label has a switching schedule or a dose conversion. Both labels say not to use them together, and each starts at its own starting dose. Semaglutide stays in the body for 5 to 7 weeks after the last dose. Your prescriber decides the timing and the dose.

Is there a Zepbound pill?

No. Zepbound comes only as a weekly injection, in a single-dose pen, single-dose vials or a 4-dose KwikPen. Wegovy has a daily tablet, approved on December 22, 2025. Lilly's weight-management pill, Foundayo, is a different molecule, orforglipron.

Which is cheaper without insurance?

As of November 13, 2026, Zepbound through LillyDirect is $299 to $449 a month by dose with on-time refills, and Wegovy is $349 a month for the injection up to 2.4 mg, $399 for 7.2 mg, and $149 to $299 for the pill. At the starting doses Zepbound is cheaper; at maintenance doses the injections are close.

Do Zepbound and Wegovy have the same boxed warning?

Yes. Both carry a boxed warning for thyroid C-cell tumors, which the drugs caused in rodents; whether they do in humans is unknown. Neither should be used by anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2.

Does Medicare cover Zepbound or Wegovy?

Medicare Part D cannot cover drugs used for obesity alone. From July 1, 2026 to December 31, 2027, the Medicare GLP-1 Bridge gives eligible Part D beneficiaries certain GLP-1 drugs for a $50 copay, with prior authorization. Lilly lists Zepbound under the Bridge, and CMS names Wegovy in its related BALANCE model.

References

  1. Eli Lilly and Company. Zepbound (tirzepatide) injection, prescribing information and Medication Guide. DailyMed, US National Library of Medicine. 2026. (sections 1, 2, 5, 6.1, 8, 12 and 14) DailyMed. ↩︎
  2. Novo Nordisk. Wegovy (semaglutide) injection and tablets, prescribing information and Medication Guide. DailyMed, US National Library of Medicine. 2026. (sections 1, 2.2–2.5, 5, 6.1, 8.3, 12.3 and 14) DailyMed. ↩︎
  3. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26–36. PubMed. PMID: 40353578. doi: 10.1056/NEJMoa2416394. SURMOUNT-5, open-label, no placebo group. Abstract read. Funded by Eli Lilly. ↩︎
  4. US Food and Drug Administration. Drugs@FDA: Mounjaro (NDA 215866) and Zepbound (NDA 217806), approval history. Drugs@FDA. 2026. accessdata.fda.gov. Approval dates read from the Drugs@FDA submission records via openFDA and checked against the FDA approval letters for NDA 215866 S-039 (pediatric, 2025-12-19), S-044 and S-045 (2026-08-27), and NDA 217806 S-041 (2026-08-26). ↩︎
  5. US Food and Drug Administration. Drugs@FDA: Ozempic (NDA 209637), Rybelsus and Ozempic tablets (NDA 213051), Wegovy injection (NDA 215256) and Wegovy tablets (NDA 218316), approval history. Drugs@FDA. 2026. accessdata.fda.gov. Approval dates read from the Drugs@FDA submission records via openFDA (api.fda.gov/drug/drugsfda.json) and checked against the FDA approval letters for NDA 215256 S-005, S-023 and S-029, NDA 213051 S-020 and S-024, and NDA 218316 (original approval 2025-12-22). ↩︎
  6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. PubMed. PMID: 35658024. doi: 10.1056/NEJMoa2206038. SURMOUNT-1. Abstract read. Funded by Eli Lilly. ↩︎
  7. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. PubMed. PMID: 33567185. doi: 10.1056/nejmoa2032183. ↩︎
  8. Eli Lilly and Company. Zepbound coverage and savings. zepbound.lilly.com. 2026. zepbound.lilly.com. Maker price page and offer terms read 2026-11-13; savings card terms end 2026-12-31. ↩︎
  9. Novo Nordisk. Wegovy savings offer and self-pay pricing. NovoCare. 2026. novocare.com. Maker price page read 2026-11-13; prices stated to be updated after 2026-12-31. ↩︎
  10. Eli Lilly and Company. A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5, NCT05822830): results. ClinicalTrials.gov. 2025. (participant flow, secondary outcomes and adverse events tables) clinicaltrials.gov. Posted results read via the ClinicalTrials.gov API: alopecia 31/374 on tirzepatide, 23/376 on semaglutide, baseline to week 72. ↩︎
  11. Pharmacy Times (Ferruggia K). Pharmacy Times. 2025. pharmacytimes.com. Trade-press report of 2025-05-14 on the SURMOUNT-5 NEJM publication; source for treatment discontinuation due to adverse events (6.1% tirzepatide, 8.0% semaglutide), a figure not in the abstract. Secondary. ↩︎
  12. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. PubMed. PMID: 37952131. doi: 10.1056/NEJMoa2307563. SELECT. Abstract read. Funded by Novo Nordisk. ↩︎
  13. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089–2099. PubMed. PMID: 40305708. doi: 10.1056/NEJMoa2413258. ESSENCE, 72-week analysis. Abstract read. Funded by Novo Nordisk. ↩︎
  14. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193–1205. PubMed. PMID: 38912654. doi: 10.1056/NEJMoa2404881. SURMOUNT-OSA. Abstract read. Funded by Eli Lilly. ↩︎
  15. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515. PubMed. PMID: 34170647. doi: 10.1056/NEJMoa2107519. SURPASS-2. Abstract read. Funded by Eli Lilly. ↩︎
  16. Eli Lilly and Company. How do I get Zepbound (tirzepatide) vials or multi-dose KwikPens? Lilly Medical (medical.lilly.com). 2026. medical.lilly.com. Maker medical-information page; date of last review 2026-02-23. ↩︎
  17. Novo Nordisk. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines), building on continued efforts to expand access. Press release (PR Newswire, via BioSpace). 2026. biospace.com. Press release of 2026-02-24. List price change effective 2027-01-01. ↩︎
  18. KFF. Medicaid Coverage of and Spending on GLP-1s. kff.org. 2026. kff.org. Analysis of 2026-01-16. ↩︎
  19. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. cms.gov. 2026. cms.gov. Page read (last modified 2026-07-13). ↩︎
  20. Centers for Medicare & Medicaid Services. BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model. cms.gov. 2026. cms.gov. Page read (last modified 2026-09-29). ↩︎
  21. KFF. 2026 Employer Health Benefits Survey. kff.org. 2026. kff.org. Survey released 2026-10-22. ↩︎
  22. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475–1503. (sections on protein, fluids, fiber and resistance training) Full text. PMID: 40445127. doi: 10.1002/oby.24336. ↩︎
Share this
← All Lighter Days articles

Free guide

The GLP-1 eating plan

Eight pages to print and keep, built protein first for days when appetite is small. Sourced, like everything on Lighter Days.

  • Seven days of four small meals, with protein and fiber counted
  • A food list: what to eat more often, and what to go easy on
  • A shopping list and a page to take to your prescriber or dietitian

You’ll also get early access to Replenish and a few emails a month. Unsubscribe any time.